Mononitron Ep (Isosorbide Mononitrate)

Isosorbide mononitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide relaxes smooth muscle in arteries and veins, lowering both preload and afterload. This decreases the heart's oxygen demand while increasing oxygen delivery to the myocardium, alleviating angina symptoms.

The specific dose of Mononitron Ep is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments may be needed for renal or hepatic impairment, and the medication is typically taken once daily as directed.

The safety of isosorbide mononitrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To request Mononitron Ep, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mononitron Ep belongs to the nitrate class, which differs from beta‑blockers or calcium‑channel blockers in its mechanism of releasing nitric oxide to dilate vessels. Nitrates are particularly effective for rapid symptom relief and prophylaxis, whereas other classes may target heart rate or calcium‑mediated contraction. Choice of therapy depends on individual patient profile and physician judgment.

Mononitron Ep should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat, and direct sunlight to maintain stability and potency throughout the shelf life.

Mononitron Ep is taken orally, usually as a whole tablet with a glass of water. It is generally prescribed for once‑daily dosing, but the exact schedule and timing should follow the prescriber’s instructions to ensure optimal therapeutic effect.

The most serious risks include severe hypotension, syncope, and rare cases of myocardial infarction or life‑threatening allergic reactions. Patients should be educated to recognize signs of dangerously low blood pressure, such as fainting or extreme dizziness, and seek immediate medical attention if they occur.

Mononitron Ep is contraindicated in patients with known hypersensitivity to isosorbide mononitrate or any nitrate, those with severe hypotension, and individuals who have recently used other nitrate preparations or phosphodiesterase‑5 inhibitors. Clinicians should also exercise caution in patients with certain cardiac conditions, such as recent myocardial infarction, unless specifically indicated.